Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2003

View Archived Issues

Schwarz updates pipeline development

Regeneron summarizes financial and development results for the first quarter

Human Genome Sciences updates plans for advancing pipeline

Combined use of two drug delivery systems after cataract surgery

Low-dose nitroglycerin delays biochemical failure after radical prostatectomy

Adherex enters screening agreement with NCI

Good oral absorption reported in humans for RSD-1235

Anti-VEGF antibody fragment safe, improves visual acuity in neovascular AMD

New data on the efficacy and safety of verteporfin phototherapy in macular degeneration

Several series of p38 MAP kinase inhibitors presented by GSK

Novel MMP-13 inhibitors claimed in recent patent literature

Antitumor platinum complex prepared and tested by Spanish researchers

Celltech R&D designs new p38 kinase inhibitors

Sanofi-Synthelabo claims new TNF-alpha production inhibitors for pain, inflammation, etc.

Boehringer Ingelheim reports novel Abeta modulators for AD and other uses

Telik reveals R&D highlights during the first quarter

Ongoing discovery and development efforts at Actelion

Phase I Davanat trial begins patient dosing

Panacea establishes Proteus diagnostics subsidiary

Launch of Klonopin Wafers

British Biotech and MerLion to develop antibacterial ribosome inhibitors

ISIS-113715 evaluated in new phase I trial for type 2 diabetes

TheraCLEC study for malabsorption completed

AVI BioPharma seeks orphan drug status for AVI-4020

Trial planned for RG-1068 in patients with schizophrenia

Wilex licenses antibody from VU University Medical Center Amsterdam

New data on the pharmacokinetics, efficacy and safety of dalbavancin

Ramoplanin is more effective than vancomycin or metronidazole in hamsters with CDAD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...